Provided by Tiger Fintech (Singapore) Pte. Ltd.

NeoGenomics

4.84
-0.2600-5.10%
Post-market: 4.910.0691+1.43%19:12 EDT
Volume:4.40M
Turnover:21.65M
Market Cap:622.88M
PE:-5.90
High:5.11
Open:5.11
Low:4.78
Close:5.10
Loading ...

NeoGenomics Faces Revenue Guidance Cut and Growth Challenges, Analyst Maintains Hold Rating

TIPRANKS
·
Yesterday

NeoGenomics Earnings Call: Growth Amid Challenges

TIPRANKS
·
Yesterday

Stock Track | NeoGenomics Plummets 5.24% Following BTIG Downgrade and Stephens' Price Target Cut

Stock Track
·
Yesterday

Stock Track | NeoGenomics Plummets 5.24% Following Analyst Downgrade and Target Price Cut

Stock Track
·
Yesterday

Market Cool On NeoGenomics, Inc.'s (NASDAQ:NEO) Revenues Pushing Shares 27% Lower

Simply Wall St.
·
Yesterday

Stock Track | NeoGenomics Soars 5% on Launch of New Liquid Biopsy Test, Defying Analyst Downgrades

Stock Track
·
30 Jul

BTIG Research Downgrades NeoGenomics to Neutral From Buy

MT Newswires Live
·
30 Jul

Neogenomics Inc : Btig Cuts to Neutral From Buy

THOMSON REUTERS
·
30 Jul

NeoGenomics Inc. Launches PanTracer LBx: A New Liquid Biopsy Test for Comprehensive Genomic Profiling in Oncology

Reuters
·
30 Jul

Neogenomics Inc : Stephens Cuts Target Price to $6.5 From $15

THOMSON REUTERS
·
30 Jul

NeoGenomics: Potential Upside Amidst Challenges and Low Valuation

TIPRANKS
·
30 Jul

NeoGenomics Cut to Market Perform From Outperform by William Blair

Dow Jones
·
30 Jul

NeoGenomics: Buy Rating Affirmed Amid Stable Growth and Strategic Focus Despite Near-Term Challenges

TIPRANKS
·
30 Jul

Stock Track | NeoGenomics Plummets 24.92% on Q2 Earnings Miss and Lowered Guidance

Stock Track
·
30 Jul

NeoGenomics downgraded to Market Perform from Outperform at William Blair

TIPRANKS
·
30 Jul

NeoGenomics (NEO) was downgraded to a Hold Rating at William Blair

TIPRANKS
·
30 Jul

Neogenomics Inc reports results for the quarter ended June 30 - Earnings Summary

Reuters
·
29 Jul

NeoGenomics reports Q2 adjusted EPS 3c, consensus 2c

TIPRANKS
·
29 Jul

NeoGenomics cuts FY25 revenue view to $720M-$726 from $747M-$759M

TIPRANKS
·
29 Jul

GUIDANCE: (NEO) NeoGenomics Expects Full Year 2025 Consolidated Revenue Range $720M - $726M, vs. FactSet Est of $743.8M

MT Newswires Live
·
29 Jul